The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 338.00
Bid: 335.00
Ask: 338.00
Change: 25.00 (7.99%)
Spread: 3.00 (0.896%)
Open: 324.00
High: 346.00
Low: 323.00
Prev. Close: 313.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

Wed, 28th Feb 2024 17:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Says it swings to net income of USD100.8 million for 2023, from a USD360.8 million net loss in 2022. Revenue rises 97% to USD838.0 million from USD426.4 million, with Oncology/Immunology consolidated revenue more than tripling to high end of guidance, at USD528.6 million. Includes USD280 million of an upfront payment from deal with Takeda Pharmaceutical Co Ltd. Cash balance at December 31 is USD886.3 million, up from USD631.0 million one year prior. Company does not recommend a final dividend, unchanged from 2022. Guides for USD300 million to USD400 million in Oncology/Immunology consolidated revenue in 2024.

----------

Cykel AI PLC - London-based artificial technologies firm, founded in August 2023 - Posts operating loss and pretax loss of GBP1.4 million for the period from August 22 to November 30. Cash balance at November 30 is GBP1.6 million. Says management team continues to develop and refine its task operating system, pending the expected reverse takeover by London-based special purpose acquisition company Mustang Energy PLC agreed in January.

----------

Harmony Energy Income Trust PLC - Great Britain-focused investor in commercial-scale battery energy storage systems - Net asset value at October 31 is 115.40 pence per share, down from 120.55p one year previously. Reports adjusted NAV total return of positive 1.2% for the year to October 31, following a positive 23.4% return the year before. Pretax profit falls to GBP3.1 million from GBP48.4 million. Company increases total dividend for year to 8p per share from 2p, and says it is working hard to find solutions to its current challenges, including the "deteriorated" Great British battery energy storage systems or BESS market. Acknowledges however that due to "unexpectedly low" income its dividends were paid using VAT rebates, "which the board recognises is not what shareholders expect over the long term".

----------

Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Pretax loss for six months to November 30 is USD114,000, widening from USD72,000 the prior year. Assets at period end total USD1.16 billion, down from USD6.43 billion one year prior. Loss per share widens to 2.95 US cents from 1.86 cents. Says investees remain at 'pre-revenue' stage of business development.

----------

Malin Corp PLC - Dublin-based investor in life sciences companies - Says cash at December 31 is EUR29.3 million, compared to USD173.9 million at the same time one year prior. This has grown to EUR34.5 million at February 26 due to receipt of a contingent milestone payment from a disposal to Sanofi SA in 2021. Estimated intrinsic equity value was EUR6.56 per share at December 31 and EUR7.91 at February 26. Company says it returns EUR140.7 million of capital to shareholders throughout 2023 with a tender offer and on-market buybacks. Company also says Executive Chair Liam Daniel's role will revert to non-executive chair from Thursday.

----------

AIQ Ltd - company focused on acquiring and developing e-commerce sector businesses - Revenue for the year to October 31 falls to GBP207,209 from GBP496,296 annually. Pretax loss widens to GBP503,198 from GBP336,731. Says these results reflect challenging environment for non-fungible tokens and other blockchain technology-based products. Cash balance at October 31 is GBP135,445, down from GBP636,459 one year prior. Company says it continues to closely monitor its cash position and "is keeping all its strategic options open should the markets not turn favourable in the near-term".

----------

Renewables Infrastructure Group Ltd - investor in wind, solar and battery storage projects in Europe, advised by InfraRed Capital Partners Ltd - NAV per share at December 31 is 127.7p, down from 134.6p one year prior. Says reduction was driven by lower power price forwards and higher valuation discount rates. Says portfolio revenue for 2023 was GBP793 million, down from GBP838 million in 2022. Portfolio earnings before interest, tax, depreciation and amortisation falls to GBP610 million from GBP677 million. Dividend for 2023 totals 7.18p per share, and company is targeting a payout of 7.47p per share for 2024. Adds that the macroeconomic environment looks more "benign" this year.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
18 Apr 2023 09:55

Hutchmed gets Chinese approval for fruquintinib new drug application

(Alliance News) - Hutchmed (China) Ltd on Tuesday said the China National Medical Products Administration accepted its new drug application for fruquintinib in combination with paclitaxel.

Read more
4 Apr 2023 13:56

Hutchmed to start registration phase enrolments for two treatments

(Alliance News) - Hutchmed China Ltd on Tuesday said it will start registration phase enrolments for two of its prospective treatments under study, HMPL-453 and savolitinib.

Read more
31 Mar 2023 13:47

Hutchmed completes rolling FDA submission for colorectal cancer drug

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced the completion of its rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor 'fruquintinib'.

Read more
31 Mar 2023 12:15

Hutchmed submits new drug application to US FDA for cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer drug to the US Food & Drug Administration.

Read more
14 Mar 2023 14:23

Hutchmed China inks global licensing deal with Takeda on fruquintinib

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical Co Ltd for fruquintinib.

Read more
8 Mar 2023 14:07

DIRECTOR DEALINGS: Hutchmed CFO banks GBP4 million; Haleon chair buys

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
28 Feb 2023 11:43

Hutchmed expects revenue climb from oncology, immunology division

(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm looks forward to a productive 2023.

Read more
27 Feb 2023 11:39

Hutchmed enrols last patient in lymphoma treatment trial

(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the treatment of relapsed or refractory follicular lymphoma (FL), which is a subtype of non-Hodgkin's lymphoma.

Read more
27 Feb 2023 11:11

Hutchmed completes patient enrolment for trial testing cancer therapy

(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its once-a-day oral monotherapy in patients with relapsed or refractory follicular lymphoma.

Read more
21 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Hochschild Mining PLCFull Year Results (TBC)
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Greencoat UK Wind PLCFull Year Results (TBC)
Harmony Energy Income Trust PLCFull Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
Friday 24 February 
ASA International Group PLCTrading Statement
CVS Group PLCHalf Year Results
European Opportunities Trust PLCHalf Year Results
Grit Real Estate Income Group LtdHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
International Consolidated Airlines Group SAFull Year Results
Jupiter Fund Management PLCFull Year Results
Monday 27 February 
Associated British Foods PLCTrading Statement
Beeks Financial Cloud Group PLCHalf Year Results
Bunzl PLCFull Year Results
Centralnic Group PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
DX Group PLCHalf Year Results
GlobalData PLCFull Year Results
Greencoat Renewables PLCFull Year Results
Kosmos Energy LtdFull Year Results
Quartix Technologies PLCFull Year Results
RHI Magnesita NVFull Year Results
Senior PLCFull Year Results
Tuesday 28 February 
abrdn PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Bluefield Solar Income Fund LtdHalf Year Results
boohoo Group PLCFull Year Results
Cap-XX LtdHalf Year Results
Croda International PLCFull Year Results
Dalata Hotel Group PLCFull Year Results
Derwent London PLCFull Year Results
Hutchmed (China) LtdFull Year Results
Intertek Group PLCFull Year Results
Kitwave Group PLCFull Year Results
Man Group PLCFull Year Results
McBride PLCHalf Year Results
Morgan Advanced Materials PLCFull Year Results
Ocado Group PLCFull Year Results
Princess Private Equity Holding LtdFull Year Results
Rotork PLCFull Year Results
St James's Place PLCFull Year Results
S-Ventures PLCFull Year Results
Travis Perkins PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Videndum PLCFull Year Results
XP Power LtdFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
23 Jan 2023 09:01

Hutchmed signs drug licensing deal with Takeda for sales outside China

(Alliance News) - Hutchmed (China) Ltd on Monday said it has signed an licensing agreement with Takeda Pharmaceutical Co Ltd for the Japanese company to commercialise Hutchmed's key cancer drug outside China.

Read more
18 Jan 2023 19:03

TRADING UPDATES: Galileo confirms gold zone; Spectral hails results

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
3 Jan 2023 13:47

Hutchmed China completes enrolment for solveplenib clinical trial

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.

Read more
3 Jan 2023 10:28

Hutchmed completes patient enrolment for ITP clinical trial in China

(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

Read more
19 Dec 2022 19:29

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.